Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04493060 · ClinicalTrials.gov registry record · Phase 2

Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer

A Phase 2 study of Stage IV Pancreatic Cancer AJCC v8 and Metastatic Pancreatic Ductal Adenocarcinoma, sponsored by Mayo Clinic.

Completed
Registry status
Phase 2
Development phase
22
Enrollment target
3
Study locations

NCT04493060 is a Phase 2 study of Stage IV Pancreatic Cancer AJCC v8 and Metastatic Pancreatic Ductal Adenocarcinoma that has completed, run by Mayo Clinic. The registered enrollment target is 22 participants, below the 88-participant average among 31 other Stage IV Pancreatic Cancer AJCC v8 trials with a reported enrollment target (75% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04493060, a Phase 2 study of Stage IV Pancreatic Cancer AJCC v8 and Metastatic Pancreatic Ductal Adenocarcinoma, has completed, sponsored by Mayo Clinic.

COMPLETED
Registry status
Phase 2
Development phase
22 participants
Enrollment target
3
Study locations

Study Summary

This phase II trial studies how well niraparib and dostarlimab work in treating patients with germline or somatic BRCA1/2 and PALB2 mutated pancreatic cancer that has spread to other places in the body (metastatic). Niraparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as dostarlimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving niraparib and dostarlimab may kill more tumor cells.

Conditions Studied

Stage IV Pancreatic Cancer AJCC v8 Metastatic Pancreatic Ductal Adenocarcinoma

Interventions

  • DRUG Niraparib
  • BIOLOGICAL Dostarlimab

Study Locations (3)

Arizona

  • Mayo Clinic in Arizona - Scottsdale

Florida

  • Mayo Clinic in Florida - Jacksonville

Minnesota

  • Mayo Clinic in Rochester - Rochester

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 2020-12-28
Est. Completion 2025-06-01
Phase Phase 2

Sponsor

Mayo Clinic

2,844 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04493060

The ClinicalTrials.gov registry entry for NCT04493060 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 88-participant average among 31 other Stage IV Pancreatic Cancer AJCC v8 trials with a reported enrollment target (75% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Stage IV Pancreatic Cancer AJCC v8 appearing as the primary indexed condition, and to 2 interventions - of which Niraparib is the first listed.

NCT04493060 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Arizona, Florida, Minnesota.

Frequently Asked Questions

What is clinical trial NCT04493060 about?

NCT04493060 is a clinical study titled "Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer". This phase II trial studies how well niraparib and dostarlimab work in treating patients with germline or somatic BRCA1/2 and PALB2 mutated pancreatic cancer that has spread to other places in the body (metastatic). Niraparib may stop the growth of tumor cells by blocking some of the enzymes needed ...

What is the current status of trial NCT04493060?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2020-12-28. Estimated completion is 2025-06-01.

What conditions does trial NCT04493060 study?

This clinical trial studies the following conditions: Stage IV Pancreatic Cancer AJCC v8, Metastatic Pancreatic Ductal Adenocarcinoma.

What interventions are being tested in trial NCT04493060?

The interventions under investigation include: Niraparib (DRUG), Dostarlimab (BIOLOGICAL).

Who is sponsoring clinical trial NCT04493060?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04493060 being conducted?

This trial has 3 study locations across Arizona, Florida, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Stage IV Pancreatic Cancer AJCC v8

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Stage IV Pancreatic Cancer AJCC v8

All registered trials for this condition

Metastatic Pancreatic Ductal Adenocarcinoma

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.